COMPANY

ClearNote Health

Location: San Diego, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Pancreatic Cancer Diagnosis of Cancer of Various Organs

Raises and deals from press releases

Raise Series D · $52M · announced May 27, 2026 Company release ↗
Source quote
- May 27, 2026 · Company release ↗
  “— ClearNote Health , a company dedicated to improving early detection for some of the deadliest cancers, today announced the close of $52 million in Series D financing”

Raises announced in these releases: $52M disclosed.

From the company’s own releases; this list is partial. All raises and deals

May 27, 2026 Raise Series D · $52M source ↗
Oct 31, 2022 Trial start Not phased (device or behavioral study): New Onset Diabetes Management for Earlier Detection of Pancreatic Cancer (NODMED) source ↗
Jun 1, 2022 Trial start Not phased (device or behavioral study): EpiDetect Study: Clinical Validation of a Pancreatic Cancer Detection Test in New-Onset Diabetes Patients source ↗
Apr 5, 2018 Trial start —: Non-invasive Liquid Biopsy Analysis of Epigenomics Signatures in Multiple Cancer Types source ↗

Jun 13, 2029 (ESTIMATED) · · Non-invasive Liquid Biopsy Analysis of Epigenomics Signatures in Multiple Cancer Types · NCT03869814

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT03869814	Non-invasive Liquid Biopsy Analysis of Epigenomics Signatures in Multiple Cancer Types	Not listed	Recruiting	Apr 5, 2018	Jun 13, 2029 (estimated)
NCT05188573	EpiDetect Study: Clinical Validation of a Pancreatic Cancer Detection Test in New-Onset Diabetes Patients	Not phased (device or behavioral study)	Withdrawn	Jun 1, 2022	Mar 31, 2025 (estimated)
NCT05188586	New Onset Diabetes Management for Earlier Detection of Pancreatic Cancer (NODMED)	Not phased (device or behavioral study)	Terminated	Oct 31, 2022	Mar 16, 2023 (actual)